Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Abemaciclib and Letrozole in Advanced ER+, MMRP, TP53 Wildtype Endometrial Cancer
NCT06366347Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib in endometrial cancer (EC), sponsored by Dana-Farber Cancer Institute. Started Sep 2024; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06366347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06366347.